Trial Outcomes & Findings for A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis (NCT NCT00814307)

Results Overview

ACR20 response: greater than or equal to (\>=) 20 percent (%) improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

611 participants

Primary outcome timeframe

Month 3

Results posted on

2013-01-18

Participant Flow

Participant milestones

Participant milestones
Measure	CP-690,550 5 mg CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo, Then CP-690,550 5 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Overall Study STARTED	244	245	61	61
Overall Study Treated	243	245	61	61
Overall Study COMPLETED	232	218	54	51
Overall Study NOT COMPLETED	12	27	7	10

Reasons for withdrawal

Reasons for withdrawal
Measure	CP-690,550 5 mg CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo, Then CP-690,550 5 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Overall Study Randomized but not treated	1	0	0	0
Overall Study Adverse Event	3	9	3	2
Overall Study Lack of Efficacy	1	1	3	4
Overall Study Other	1	2	0	1
Overall Study Protocol Violation	2	8	1	1
Overall Study Withdrawal by Subject	4	6	0	2
Overall Study Death	0	1	0	0

Baseline Characteristics

A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	CP-690,550 5 mg n=243 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=245 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo, Then CP-690,550 5 mg n=61 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet twice daily from Month 3 up to Month 6 or early termination.	Placebo, Then CP-690,550 10 mg n=61 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.	Total n=610 Participants Total of all reporting groups
Age Continuous	52.2 Years STANDARD_DEVIATION 11.5 • n=5 Participants	52.4 Years STANDARD_DEVIATION 11.7 • n=7 Participants	50.7 Years STANDARD_DEVIATION 12.8 • n=5 Participants	48.8 Years STANDARD_DEVIATION 11.9 • n=4 Participants	51.8 Years STANDARD_DEVIATION 11.8 • n=21 Participants
Sex: Female, Male Female	207 Participants n=5 Participants	216 Participants n=7 Participants	54 Participants n=5 Participants	51 Participants n=4 Participants	528 Participants n=21 Participants
Sex: Female, Male Male	36 Participants n=5 Participants	29 Participants n=7 Participants	7 Participants n=5 Participants	10 Participants n=4 Participants	82 Participants n=21 Participants

PRIMARY outcome

Timeframe: Month 3

Population: Full Analysis Set (FAS): all randomized participants who received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed)=participants evaluable for this measure.

ACR20 response: greater than or equal to (\>=) 20 percent (%) improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=241 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=242 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=120 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 3	59.75 percentage of participants	65.70 percentage of participants	26.67 percentage of participants	—

PRIMARY outcome

Timeframe: Baseline, Month 3

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n' signifies those participants who were evaluable at given time points for each group respectively.

HAQ-DI: participant-reported assessment of ability to perform tasks in 8 functional categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3, 0=least functional difficulty and 3=extreme functional difficulty.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=240 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=241 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=122 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Month 3 Baseline (n=240,241,122)	1.53 units on a scale Standard Deviation 0.66	1.50 units on a scale Standard Deviation 0.64	1.53 units on a scale Standard Deviation 0.65	—
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Month 3 Change at Month 3 (n=237,227,109)	-0.48 units on a scale Standard Deviation 0.66	-0.54 units on a scale Standard Deviation 0.60	-0.18 units on a scale Standard Deviation 0.61	—

PRIMARY outcome

Timeframe: Month 3

Population: FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

DAS28-4 (ESR) calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hour\]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (=\<) 3.2 implied low disease activity, greater than (\>) 3.2 to 5.1 implied moderate to high disease activity and less than (\<) 2.6=remission.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=229 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=219 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=104 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Percentage of Participant With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 3	6.11 percentage of participants	10.05 percentage of participants	4.81 percentage of participants	—

SECONDARY outcome

Timeframe: Week 2, Month 1, 2

Population: FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

ACR20 response: \>= 20% improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=241 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=242 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=120 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 2, Month 1 and 2 Week 2	29.58 percentage of participants	39.17 percentage of participants	11.76 percentage of participants	—
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 2, Month 1 and 2 Month 1	46.47 percentage of participants	52.07 percentage of participants	21.67 percentage of participants	—
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 2, Month 1 and 2 Month 2	56.85 percentage of participants	60.74 percentage of participants	25.83 percentage of participants	—

SECONDARY outcome

Timeframe: Month 4, 5, 6

Population: FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

ACR20 response: \>= 20% improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=241 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=242 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=60 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=60 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 4, 5 and 6 Month 4	69.29 percentage of participants	69.01 percentage of participants	51.67 percentage of participants	61.67 percentage of participants
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 4, 5 and 6 Month 5	68.46 percentage of participants	69.83 percentage of participants	61.67 percentage of participants	63.33 percentage of participants
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 4, 5 and 6 Month 6	69.29 percentage of participants	71.07 percentage of participants	58.33 percentage of participants	56.67 percentage of participants

SECONDARY outcome

Timeframe: Week 2, Month 1, 2, 3

Population: FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

ACR50 response: greater than or equal to \>=50% improvement in tender joint count; \>=50% improvement in swollen joint count; and \>=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=241 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=242 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=120 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 2, Month 1, 2 and 3 Week 2	5.83 percentage of participants	12.92 percentage of participants	4.20 percentage of participants	—
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 2, Month 1, 2 and 3 Month 1	17.43 percentage of participants	23.97 percentage of participants	4.17 percentage of participants	—
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 2, Month 1, 2 and 3 Month 2	26.14 percentage of participants	33.88 percentage of participants	5.83 percentage of participants	—
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 2, Month 1, 2 and 3 Month 3	31.12 percentage of participants	36.78 percentage of participants	12.50 percentage of participants	—

SECONDARY outcome

Timeframe: Month 4, 5, 6

Population: FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

ACR50 response: greater than or equal to \>=50% improvement in tender joint count; \>=50% improvement in swollen joint count; and \>=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=241 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=242 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=60 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=60 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 4, 5 and 6 Month 4	37.34 percentage of participants	42.98 percentage of participants	28.33 percentage of participants	28.33 percentage of participants
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 4, 5 and 6 Month 5	39.42 percentage of participants	45.45 percentage of participants	36.67 percentage of participants	35.00 percentage of participants
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 4, 5 and 6 Month 6	41.91 percentage of participants	46.69 percentage of participants	33.33 percentage of participants	33.33 percentage of participants

SECONDARY outcome

Timeframe: Week 2, Month 1, 2, 3

Population: FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

ACR70 response: \>=70% improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=241 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=242 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=120 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 2, Month 1, 2 and 3 Week 2	2.08 percentage of participants	4.58 percentage of participants	0.00 percentage of participants	—
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 2, Month 1, 2 and 3 Month 1	4.98 percentage of participants	9.09 percentage of participants	1.67 percentage of participants	—
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 2, Month 1, 2 and 3 Month 2	9.96 percentage of participants	19.01 percentage of participants	3.33 percentage of participants	—
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 2, Month 1, 2 and 3 Month 3	15.35 percentage of participants	20.25 percentage of participants	5.83 percentage of participants	—

SECONDARY outcome

Timeframe: Month 4, 5, 6

Population: FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

ACR70 response: \>=70% improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=241 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=242 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=60 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=60 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 4, 5 and 6 Month 6	21.99 percentage of participants	29.34 percentage of participants	20.00 percentage of participants	21.67 percentage of participants
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 4, 5 and 6 Month 4	19.92 percentage of participants	26.03 percentage of participants	13.33 percentage of participants	15.00 percentage of participants
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 4, 5 and 6 Month 5	21.16 percentage of participants	28.51 percentage of participants	18.33 percentage of participants	18.33 percentage of participants

SECONDARY outcome

Timeframe: Baseline, Month 3

Population: FAS population. 'N' (number of participants analyzed)=participants evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PtGA of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =\<3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity and \<2.6 implied remission.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=236 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=234 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=115 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Baseline and Month 3 Baseline (n= 236, 234, 115)	6.71 units on a scale Standard Deviation 0.93	6.70 units on a scale Standard Deviation 0.94	6.65 units on a scale Standard Deviation 0.93	—
Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Baseline and Month 3 Month 3 (n= 229, 219, 104)	4.78 units on a scale Standard Deviation 1.37	4.55 units on a scale Standard Deviation 1.39	5.54 units on a scale Standard Deviation 1.46	—

SECONDARY outcome

Timeframe: Month 6

Population: FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

DAS28-4 (ESR) calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hour\]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (=\<) 3.2 implied low disease activity, greater than (\>) 3.2 to 5.1 implied moderate to high disease activity and less than (\<) 2.6=remission.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=221 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=209 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=52 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=47 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Month 6	4.33 units on a scale Standard Deviation 1.39	4.01 units on a scale Standard Deviation 1.38	4.31 units on a scale Standard Deviation 1.34	3.98 units on a scale Standard Deviation 1.50

SECONDARY outcome

Timeframe: Baseline, Week 2, Month 1, 2, 3

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (milligram per liter \[mg/L\]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =\<3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity and \<2.6 implied remission.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=239 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=242 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=121 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Week 2, Month 1, 2 and 3 Baseline (n= 239, 242, 121)	5.68 units on a scale Standard Deviation 0.90	5.60 units on a scale Standard Deviation 0.91	5.56 units on a scale Standard Deviation 0.85	—
Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Week 2, Month 1, 2 and 3 Week 2 (n= 234, 231, 118)	4.79 units on a scale Standard Deviation 1.12	4.42 units on a scale Standard Deviation 1.11	5.30 units on a scale Standard Deviation 1.13	—
Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Week 2, Month 1, 2 and 3 Month 1 (n= 237, 236, 115)	4.41 units on a scale Standard Deviation 1.12	3.99 units on a scale Standard Deviation 1.26	4.98 units on a scale Standard Deviation 1.25	—
Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Week 2, Month 1, 2 and 3 Month 2 (n= 238, 233, 109)	4.02 units on a scale Standard Deviation 1.26	3.64 units on a scale Standard Deviation 1.27	4.85 units on a scale Standard Deviation 1.36	—
Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Week 2, Month 1, 2 and 3 Month 3 (n= 238, 229, 109)	3.89 units on a scale Standard Deviation 1.27	3.59 units on a scale Standard Deviation 1.27	4.68 units on a scale Standard Deviation 1.27	—

SECONDARY outcome

Timeframe: Month 4, 5, 6

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =\<3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity and \<2.6 implied remission.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=235 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=222 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=55 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=50 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Month 4, 5 and 6 Month 4 (n= 235, 222, 54, 48)	3.65 units on a scale Standard Deviation 1.24	3.26 units on a scale Standard Deviation 1.22	3.89 units on a scale Standard Deviation 1.19	3.50 units on a scale Standard Deviation 1.28
Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Month 4, 5 and 6 Month 5 (n= 231, 219, 55, 50)	3.54 units on a scale Standard Deviation 1.26	3.12 units on a scale Standard Deviation 1.24	3.53 units on a scale Standard Deviation 1.25	3.34 units on a scale Standard Deviation 1.26
Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Month 4, 5 and 6 Month 6 (n= 228, 215, 53, 50)	3.48 units on a scale Standard Deviation 1.23	3.11 units on a scale Standard Deviation 1.26	3.56 units on a scale Standard Deviation 1.32	3.12 units on a scale Standard Deviation 1.34

SECONDARY outcome

Timeframe: Baseline, Week 2, Month 1, 2, 3

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

HAQ-DI: participant-reported assessment of ability to perform tasks in 8 functional categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3, 0=least functional difficulty and 3=extreme functional difficulty.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=240 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=241 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=122 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Health Assessment Questionnaire Disability Index (HAQ-DI) at Baseline, Week 2, Month 1, 2 and 3 Baseline (n= 240, 241, 122)	1.53 units on a scale Standard Deviation 0.66	1.50 units on a scale Standard Deviation 0.64	1.53 units on a scale Standard Deviation 0.65	—
Health Assessment Questionnaire Disability Index (HAQ-DI) at Baseline, Week 2, Month 1, 2 and 3 Week 2 (n= 240, 239, 119)	1.27 units on a scale Standard Deviation 0.62	1.21 units on a scale Standard Deviation 0.65	1.43 units on a scale Standard Deviation 0.64	—
Health Assessment Questionnaire Disability Index (HAQ-DI) at Baseline, Week 2, Month 1, 2 and 3 Month 1 (n= 237, 240, 116)	1.18 units on a scale Standard Deviation 0.68	1.09 units on a scale Standard Deviation 0.66	1.40 units on a scale Standard Deviation 0.64	—
Health Assessment Questionnaire Disability Index (HAQ-DI) at Baseline, Week 2, Month 1, 2 and 3 Month 2 (n= 240, 233, 110)	1.05 units on a scale Standard Deviation 0.66	0.97 units on a scale Standard Deviation 0.68	1.40 units on a scale Standard Deviation 0.68	—
Health Assessment Questionnaire Disability Index (HAQ-DI) at Baseline, Week 2, Month 1, 2 and 3 Month 3 (n= 238, 229, 109)	1.05 units on a scale Standard Deviation 0.70	0.97 units on a scale Standard Deviation 0.69	1.35 units on a scale Standard Deviation 0.73	—

SECONDARY outcome

Timeframe: Month 4, 5, 6

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

HAQ-DI: participant-reported assessment of ability to perform tasks in 8 functional categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3, 0=least functional difficulty and 3=extreme functional difficulty.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=235 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=223 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=55 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=50 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Health Assessment Questionnaire Disability Index (HAQ-DI) at Month 4, 5 and 6 Month 4 (n= 235, 223, 55, 49)	0.97 units on a scale Standard Deviation 0.66	0.88 units on a scale Standard Deviation 0.68	1.08 units on a scale Standard Deviation 0.70	1.09 units on a scale Standard Deviation 0.65
Health Assessment Questionnaire Disability Index (HAQ-DI) at Month 4, 5 and 6 Month 5 (n= 231, 221, 55, 50)	0.95 units on a scale Standard Deviation 0.69	0.87 units on a scale Standard Deviation 0.69	1.04 units on a scale Standard Deviation 0.59	1.03 units on a scale Standard Deviation 0.64
Health Assessment Questionnaire Disability Index (HAQ-DI) at Month 4, 5 and 6 Month 6 (n= 229, 216, 54, 50)	0.94 units on a scale Standard Deviation 0.68	0.86 units on a scale Standard Deviation 0.67	1.05 units on a scale Standard Deviation 0.63	1.00 units on a scale Standard Deviation 0.66

SECONDARY outcome

Timeframe: Baseline, Week 2, Month 1, 2, 3

Population: FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'n'=participants evaluable at given time point for each group respectively.

Participants assessed the severity of their arthritis pain using a 100 millimeter (mm) visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (most severe pain), measurement on a scale corresponds to the magnitude of their pain.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=241 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=243 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=122 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Patient Assessment of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3 Baseline (n= 241, 243, 122)	61.35 mm Standard Deviation 22.27	62.03 mm Standard Deviation 23.63	61.79 mm Standard Deviation 21.27	—
Patient Assessment of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3 Week 2 (n= 239, 239, 119)	45.92 mm Standard Deviation 22.87	42.13 mm Standard Deviation 25.06	55.61 mm Standard Deviation 23.63	—
Patient Assessment of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3 Month 1 (n= 237, 240, 116)	40.68 mm Standard Deviation 23.04	36.86 mm Standard Deviation 24.46	52.47 mm Standard Deviation 24.59	—
Patient Assessment of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3 Month 2 (n= 240, 233, 110)	36.39 mm Standard Deviation 23.29	31.66 mm Standard Deviation 24.38	52.38 mm Standard Deviation 26.09	—
Patient Assessment of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3 Month 3 (n= 237, 228, 108)	34.93 mm Standard Deviation 23.73	31.37 mm Standard Deviation 24.35	49.84 mm Standard Deviation 25.10	—

SECONDARY outcome

Timeframe: Month 4, 5, 6

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

Participants assessed the severity of their arthritis pain using a 100 mm visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (most severe pain), measurement on a scale corresponds to the magnitude of their pain.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=235 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=223 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=55 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=50 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Patient Assessment of Arthritis Pain at Month 4, 5 and 6 Month 4 (n= 235, 223, 55, 49)	33.18 mm Standard Deviation 23.02	29.70 mm Standard Deviation 23.21	34.27 mm Standard Deviation 24.53	35.47 mm Standard Deviation 25.28
Patient Assessment of Arthritis Pain at Month 4, 5 and 6 Month 5 (n= 231, 221, 55, 50)	32.63 mm Standard Deviation 23.07	29.10 mm Standard Deviation 22.24	34.05 mm Standard Deviation 23.48	35.06 mm Standard Deviation 24.82
Patient Assessment of Arthritis Pain at Month 4, 5 and 6 Month 6 (n= 228, 216, 54, 50)	32.60 mm Standard Deviation 23.55	27.89 mm Standard Deviation 23.17	33.96 mm Standard Deviation 24.62	32.28 mm Standard Deviation 23.79

SECONDARY outcome

Timeframe: Baseline, Week 2, Month 1, 2, 3

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm Visual Analog Scale where 0 = very well and 100 = very poorly.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=240 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=243 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=122 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3 Baseline (n= 240, 243, 122)	61.66 mm Standard Deviation 22.00	63.46 mm Standard Deviation 23.23	62.63 mm Standard Deviation 21.91	—
Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3 Week 2 (n= 240, 239, 119)	46.34 mm Standard Deviation 22.36	41.32 mm Standard Deviation 24.90	55.95 mm Standard Deviation 23.79	—
Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3 Month 1 (n= 237, 240, 116)	39.63 mm Standard Deviation 22.36	37.69 mm Standard Deviation 23.94	53.23 mm Standard Deviation 24.01	—
Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3 Month 2 (n= 240, 233, 110)	36.29 mm Standard Deviation 22.20	32.56 mm Standard Deviation 23.47	53.05 mm Standard Deviation 26.04	—
Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3 Month 3 (n= 238, 229, 108)	35.90 mm Standard Deviation 23.61	32.78 mm Standard Deviation 23.75	50.48 mm Standard Deviation 25.82	—

SECONDARY outcome

Timeframe: Month 4, 5, 6

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm Visual Analog Scale where 0 = very well and 100 = very poorly.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=235 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=223 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=55 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=50 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Patient Global Assessment (PtGA) of Arthritis Pain at Month 4, 5 and 6 Month 4 (n= 235, 223, 55, 49)	33.59 mm Standard Deviation 22.44	29.69 mm Standard Deviation 22.25	35.27 mm Standard Deviation 23.77	36.45 mm Standard Deviation 25.92
Patient Global Assessment (PtGA) of Arthritis Pain at Month 4, 5 and 6 Month 5 (n= 231, 221, 55, 50)	34.59 mm Standard Deviation 23.37	29.37 mm Standard Deviation 22.13	32.88 mm Standard Deviation 21.43	33.96 mm Standard Deviation 25.02
Patient Global Assessment (PtGA) of Arthritis Pain at Month 4, 5 and 6 Month 6 (n= 228, 216, 54, 50)	32.56 mm Standard Deviation 23.09	29.52 mm Standard Deviation 22.89	33.51 mm Standard Deviation 24.00	32.89 mm Standard Deviation 23.78

SECONDARY outcome

Timeframe: Baseline, Week 2, Month 1, 2, 3

Population: FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'n'=participants evaluable at given time point for each group respectively.

Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=241 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=243 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=122 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Physician Global Assessment (PGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3 Baseline (n= 241, 243, 122)	61.46 mm Standard Deviation 16.93	60.84 mm Standard Deviation 16.84	62.22 mm Standard Deviation 16.85	—
Physician Global Assessment (PGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3 Week 2 (n= 239, 240, 119)	43.43 mm Standard Deviation 17.69	40.47 mm Standard Deviation 19.73	52.15 mm Standard Deviation 19.25	—
Physician Global Assessment (PGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3 Month 1 (n= 237, 240, 116)	35.89 mm Standard Deviation 18.91	33.99 mm Standard Deviation 20.37	46.98 mm Standard Deviation 22.29	—
Physician Global Assessment (PGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3 Month 2 (n= 240, 232, 110)	32.06 mm Standard Deviation 20.81	26.75 mm Standard Deviation 19.23	44.45 mm Standard Deviation 23.62	—
Physician Global Assessment (PGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2 and 3 Month 3 (n= 238, 229, 109)	29.20 mm Standard Deviation 19.98	24.47 mm Standard Deviation 18.42	42.05 mm Standard Deviation 23.58	—

SECONDARY outcome

Timeframe: Month 4, 5, 6

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=235 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=221 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=55 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=50 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Physician Global Assessment (PGA) of Arthritis Pain at Month 4, 5 and 6 Month 4 (n= 235, 221, 54, 49)	25.30 mm Standard Deviation 18.56	21.21 mm Standard Deviation 16.46	27.48 mm Standard Deviation 19.80	25.86 mm Standard Deviation 20.32
Physician Global Assessment (PGA) of Arthritis Pain at Month 4, 5 and 6 Month 5 (n= 231, 221, 55, 50)	23.60 mm Standard Deviation 17.63	20.99 mm Standard Deviation 16.13	24.74 mm Standard Deviation 17.93	25.90 mm Standard Deviation 19.85
Physician Global Assessment (PGA) of Arthritis Pain at Month 4, 5 and 6 Month 6 (n= 229, 216, 54, 50)	23.26 mm Standard Deviation 18.12	20.61 mm Standard Deviation 16.27	26.16 mm Standard Deviation 19.55	21.54 mm Standard Deviation 17.51

SECONDARY outcome

Timeframe: Baseline, Month 3

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0- 100, where higher score represents higher level of functioning.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=239 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=243 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=122 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Baseline:Physical functioning (n=239,243,122)	30.09 units on a scale Standard Deviation 9.31	30.51 units on a scale Standard Deviation 8.76	31.41 units on a scale Standard Deviation 9.66	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Baseline:Role Physical (n=239,243,122)	32.84 units on a scale Standard Deviation 8.87	33.45 units on a scale Standard Deviation 8.69	33.33 units on a scale Standard Deviation 8.97	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Baseline:Social Functioning (n=239,243,122)	36.78 units on a scale Standard Deviation 11.04	36.07 units on a scale Standard Deviation 11.27	35.16 units on a scale Standard Deviation 10.34	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Baseline:Bodily Pain (n=239,243,122)	32.41 units on a scale Standard Deviation 7.57	32.74 units on a scale Standard Deviation 7.55	32.77 units on a scale Standard Deviation 7.67	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Baseline:Mental Health (n=239,243,122)	40.05 units on a scale Standard Deviation 11.49	40.50 units on a scale Standard Deviation 12.57	38.43 units on a scale Standard Deviation 12.36	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Baseline:Role Emotional (n=239,243,122)	34.26 units on a scale Standard Deviation 12.63	36.70 units on a scale Standard Deviation 13.03	35.17 units on a scale Standard Deviation 13.11	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Baseline:Vitality (n=239,243,122)	41.22 units on a scale Standard Deviation 10.06	41.04 units on a scale Standard Deviation 10.27	40.13 units on a scale Standard Deviation 9.82	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Baseline:General health perception(n=239,243,122)	34.86 units on a scale Standard Deviation 8.72	35.71 units on a scale Standard Deviation 8.86	34.70 units on a scale Standard Deviation 9.00	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Baseline:Mental Component (n=239,243,122)	41.36 units on a scale Standard Deviation 11.68	42.19 units on a scale Standard Deviation 12.44	39.87 units on a scale Standard Deviation 11.62	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Baseline:Physical Component (n=239,243,122)	31.23 units on a scale Standard Deviation 8.03	31.37 units on a scale Standard Deviation 7.39	32.21 units on a scale Standard Deviation 8.35	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Month 3:Physical functioning(n=235,224,108)	36.13 units on a scale Standard Deviation 10.44	37.05 units on a scale Standard Deviation 10.58	32.93 units on a scale Standard Deviation 10.63	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Month 3:Role Physical (n=233,224,107)	38.90 units on a scale Standard Deviation 9.41	40.45 units on a scale Standard Deviation 9.90	35.19 units on a scale Standard Deviation 9.72	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Month 3:Social Functioning(n=235,224,108)	41.62 units on a scale Standard Deviation 10.90	43.25 units on a scale Standard Deviation 9.95	36.14 units on a scale Standard Deviation 10.04	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Month 3:Bodily Pain (n=235,224,108)	40.56 units on a scale Standard Deviation 9.38	43.08 units on a scale Standard Deviation 9.50	36.35 units on a scale Standard Deviation 8.81	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Month 3:Mental Health (n=235,224,108)	44.33 units on a scale Standard Deviation 11.50	45.13 units on a scale Standard Deviation 11.25	40.73 units on a scale Standard Deviation 10.73	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Month 3:Role Emotional (n=233,224,107)	38.76 units on a scale Standard Deviation 12.13	40.84 units on a scale Standard Deviation 11.57	36.08 units on a scale Standard Deviation 12.66	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Month 3:Vitality (n=235,224,108)	47.36 units on a scale Standard Deviation 10.69	49.03 units on a scale Standard Deviation 9.86	42.23 units on a scale Standard Deviation 9.75	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Month 3:General health perception(n=235,224,108)	39.52 units on a scale Standard Deviation 9.37	41.50 units on a scale Standard Deviation 9.78	37.22 units on a scale Standard Deviation 8.75	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Month 3:Mental Component (n=233,224,107)	45.21 units on a scale Standard Deviation 11.65	46.58 units on a scale Standard Deviation 10.81	41.13 units on a scale Standard Deviation 10.90	—
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 3 Month 3:Physical Component (n=233,224,107)	38.03 units on a scale Standard Deviation 9.18	39.69 units on a scale Standard Deviation 9.31	34.58 units on a scale Standard Deviation 8.94	—

SECONDARY outcome

Timeframe: Month 6

Population: FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0- 100, where higher score represents higher level of functioning.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=229 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=216 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=54 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=50 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
36-Item Short-Form Health Survey (SF-36) at Month 6 Mental component	45.43 units on a scale Standard Deviation 11.58	46.08 units on a scale Standard Deviation 10.44	43.29 units on a scale Standard Deviation 12.37	48.76 units on a scale Standard Deviation 11.06
36-Item Short-Form Health Survey (SF-36) at Month 6 Physical functioning	36.99 units on a scale Standard Deviation 10.07	38.43 units on a scale Standard Deviation 10.67	35.74 units on a scale Standard Deviation 10.23	35.26 units on a scale Standard Deviation 9.98
36-Item Short-Form Health Survey (SF-36) at Month 6 Role Physical	39.85 units on a scale Standard Deviation 9.57	40.93 units on a scale Standard Deviation 9.50	38.25 units on a scale Standard Deviation 9.73	38.97 units on a scale Standard Deviation 9.06
36-Item Short-Form Health Survey (SF-36) at Month 6 Social Functioning	42.36 units on a scale Standard Deviation 10.60	42.98 units on a scale Standard Deviation 10.15	39.57 units on a scale Standard Deviation 11.45	43.39 units on a scale Standard Deviation 9.78
36-Item Short-Form Health Survey (SF-36) at Month 6 Bodily Pain	41.80 units on a scale Standard Deviation 9.55	43.67 units on a scale Standard Deviation 9.54	40.80 units on a scale Standard Deviation 9.36	42.19 units on a scale Standard Deviation 9.46
36-Item Short-Form Health Survey (SF-36) at Month 6 Mental Health	43.98 units on a scale Standard Deviation 12.18	45.05 units on a scale Standard Deviation 11.01	42.14 units on a scale Standard Deviation 11.90	47.03 units on a scale Standard Deviation 10.62
36-Item Short-Form Health Survey (SF-36) at Month 6 Role Emotional	40.37 units on a scale Standard Deviation 11.32	41.03 units on a scale Standard Deviation 11.47	39.04 units on a scale Standard Deviation 12.93	42.66 units on a scale Standard Deviation 12.10
36-Item Short-Form Health Survey (SF-36) at Month 6 Vitality	47.47 units on a scale Standard Deviation 10.58	48.89 units on a scale Standard Deviation 10.29	45.08 units on a scale Standard Deviation 9.50	47.88 units on a scale Standard Deviation 9.19
36-Item Short-Form Health Survey (SF-36) at Month 6 General health perception	41.05 units on a scale Standard Deviation 9.24	42.58 units on a scale Standard Deviation 9.84	38.99 units on a scale Standard Deviation 8.73	40.42 units on a scale Standard Deviation 10.83
36-Item Short-Form Health Survey (SF-36) at Month 6 Physical component	39.24 units on a scale Standard Deviation 8.42	40.89 units on a scale Standard Deviation 9.04	37.89 units on a scale Standard Deviation 9.56	37.06 units on a scale Standard Deviation 9.14

SECONDARY outcome

Timeframe: Baseline, Month 3

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no). 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range\*100);total score range:0-100,higher score=more intensity of attribute.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=239 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=242 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=122 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3 Month 3:overall sleep problem(n=236,228,109)	35.53 units on a scale Standard Deviation 19.30	33.29 units on a scale Standard Deviation 19.96	41.13 units on a scale Standard Deviation 21.31	—
Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3 Month 3:sleep problem summary(n=236,228,109)	34.46 units on a scale Standard Deviation 19.89	33.25 units on a scale Standard Deviation 20.16	40.55 units on a scale Standard Deviation 22.02	—
Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3 Month 3:somnolence(n=236,229,109)	30.28 units on a scale Standard Deviation 21.28	30.45 units on a scale Standard Deviation 21.26	35.66 units on a scale Standard Deviation 23.01	—
Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3 Month 3:snoring(n=236,229,109)	32.63 units on a scale Standard Deviation 29.61	25.85 units on a scale Standard Deviation 27.57	27.52 units on a scale Standard Deviation 29.79	—
Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3 Month 3:quantity(n=237,228,109)	6.77 units on a scale Standard Deviation 1.63	6.89 units on a scale Standard Deviation 1.45	6.78 units on a scale Standard Deviation 1.47	—
Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3 Month 3:sleep disturbance(n=236,229,109)	36.58 units on a scale Standard Deviation 24.67	32.58 units on a scale Standard Deviation 24.27	41.16 units on a scale Standard Deviation 27.40	—
Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3 Month 3:awaken short of breath(n=236,228,109)	15.93 units on a scale Standard Deviation 21.29	16.23 units on a scale Standard Deviation 21.69	22.20 units on a scale Standard Deviation 24.99	—
Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3 Month 3:adequacy(n=236,229,109)	51.69 units on a scale Standard Deviation 28.77	52.93 units on a scale Standard Deviation 27.75	44.40 units on a scale Standard Deviation 27.67	—
Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3 Baseline:overall sleep problem(n=238,242,122)	42.45 units on a scale Standard Deviation 18.38	43.09 units on a scale Standard Deviation 20.41	47.32 units on a scale Standard Deviation 21.24	—
Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3 Baseline:sleep problem summary(n=239,242,122)	40.59 units on a scale Standard Deviation 18.98	42.38 units on a scale Standard Deviation 21.01	45.98 units on a scale Standard Deviation 21.85	—
Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3 Baseline:snoring(n=238,243,121)	35.71 units on a scale Standard Deviation 31.07	30.29 units on a scale Standard Deviation 30.50	30.25 units on a scale Standard Deviation 31.42	—
Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3 Baseline:somnolence(n=239,243,122)	37.21 units on a scale Standard Deviation 22.47	37.64 units on a scale Standard Deviation 21.76	36.56 units on a scale Standard Deviation 21.29	—
Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3 Baseline:quantity(n=240,243,122)	6.53 units on a scale Standard Deviation 1.56	6.38 units on a scale Standard Deviation 1.63	6.37 units on a scale Standard Deviation 1.74	—
Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3 Baseline:sleep disturbance(n=238,242,122)	44.44 units on a scale Standard Deviation 24.11	43.33 units on a scale Standard Deviation 26.18	51.27 units on a scale Standard Deviation 25.89	—
Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3 Baseline:awaken short of breath(n=239,243,122)	18.16 units on a scale Standard Deviation 23.76	20.91 units on a scale Standard Deviation 25.47	24.92 units on a scale Standard Deviation 29.35	—
Medical Outcome Study Sleep Scale (MOS-SS) at Baseline and Month 3 Baseline:adequacy(n=239,243,122)	45.44 units on a scale Standard Deviation 27.25	42.63 units on a scale Standard Deviation 27.37	40.08 units on a scale Standard Deviation 28.36	—

SECONDARY outcome

Timeframe: Baseline, Month 3

Population: FAS population. 'n'=participants evaluable at given time point for each group respectively.

MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=241 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=243 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=122 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Baseline and Month 3 Baseline(n=241,243,122)	96 participants	98 participants	45 participants	—
Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Baseline and Month 3 Month 3(n=238,229,109)	113 participants	117 participants	52 participants	—

SECONDARY outcome

Timeframe: Month 6

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no). 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range\*100);total score range:0-100,higher score=more intensity of attribute.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=229 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=214 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=54 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=50 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Medical Outcome Study Sleep Scale (MOS-SS) at Month 6 Overall sleep problem	35.68 units on a scale Standard Deviation 18.80	33.33 units on a scale Standard Deviation 19.19	37.29 units on a scale Standard Deviation 19.26	35.64 units on a scale Standard Deviation 21.20
Medical Outcome Study Sleep Scale (MOS-SS) at Month 6 Snoring	35.28 units on a scale Standard Deviation 31.04	27.79 units on a scale Standard Deviation 28.24	26.30 units on a scale Standard Deviation 28.50	29.20 units on a scale Standard Deviation 27.47
Medical Outcome Study Sleep Scale (MOS-SS) at Month 6 Quantity	6.64 units on a scale Standard Deviation 1.45	6.87 units on a scale Standard Deviation 1.71	6.65 units on a scale Standard Deviation 1.52	6.64 units on a scale Standard Deviation 1.27
Medical Outcome Study Sleep Scale (MOS-SS) at Month 6 Sleep problem summary	35.17 units on a scale Standard Deviation 18.81	33.33 units on a scale Standard Deviation 19.66	37.41 units on a scale Standard Deviation 20.30	35.87 units on a scale Standard Deviation 20.80
Medical Outcome Study Sleep Scale (MOS-SS) at Month 6 Somnolence	30.26 units on a scale Standard Deviation 21.01	29.42 units on a scale Standard Deviation 20.64	31.36 units on a scale Standard Deviation 19.75	29.60 units on a scale Standard Deviation 21.56
Medical Outcome Study Sleep Scale (MOS-SS) at Month 6 Sleep disturbance	35.75 units on a scale Standard Deviation 25.11	33.38 units on a scale Standard Deviation 23.91	37.80 units on a scale Standard Deviation 23.96	33.80 units on a scale Standard Deviation 25.83
Medical Outcome Study Sleep Scale (MOS-SS) at Month 6 Awaken short of breath	15.55 units on a scale Standard Deviation 21.67	15.70 units on a scale Standard Deviation 21.41	21.11 units on a scale Standard Deviation 21.43	23.20 units on a scale Standard Deviation 25.67
Medical Outcome Study Sleep Scale (MOS-SS) at Month 6 Adequacy(n=229,214,54,50)	48.52 units on a scale Standard Deviation 27.41	53.04 units on a scale Standard Deviation 29.14	49.44 units on a scale Standard Deviation 29.36	49.00 units on a scale Standard Deviation 27.94

SECONDARY outcome

Timeframe: Month 6

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=229 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=216 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=54 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=50 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Month 6	105 participants	107 participants	23 participants	25 participants

SECONDARY outcome

Timeframe: Baseline, Month 3

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=240 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=243 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=122 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Baseline and Month 3 Baseline (n= 240, 243, 122)	27.90 units on a scale Standard Deviation 10.70	27.72 units on a scale Standard Deviation 11.15	27.17 units on a scale Standard Deviation 10.88	—
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Baseline and Month 3 Month 3 (n= 237, 227, 109)	34.40 units on a scale Standard Deviation 10.65	35.42 units on a scale Standard Deviation 9.75	30.06 units on a scale Standard Deviation 10.87	—

SECONDARY outcome

Timeframe: Month 6

Population: FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=229 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=216 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=54 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=50 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Month 6	34.58 units on a scale Standard Deviation 10.69	36.30 units on a scale Standard Deviation 10.10	33.63 units on a scale Standard Deviation 9.29	36.46 units on a scale Standard Deviation 9.27

SECONDARY outcome

Timeframe: Baseline, Month 3

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=240 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=243 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=122 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Baseline and Month 3 Baseline (n= 240, 243, 122)	0.41 units on a scale Standard Deviation 0.32	0.39 units on a scale Standard Deviation 0.32	0.42 units on a scale Standard Deviation 0.31	—
Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Baseline and Month 3 Month 3 (n= 237, 227, 108)	0.60 units on a scale Standard Deviation 0.25	0.66 units on a scale Standard Deviation 0.23	0.51 units on a scale Standard Deviation 0.31	—

SECONDARY outcome

Timeframe: Month 6

Population: FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=227 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=214 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=54 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=49 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Month 6	0.63 units on a scale Standard Deviation 0.23	0.68 units on a scale Standard Deviation 0.22	0.58 units on a scale Standard Deviation 0.29	0.65 units on a scale Standard Deviation 0.21

SECONDARY outcome

Timeframe: Baseline, Month 3

Population: FAS population. Participants with at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint were included. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost:visit to doctor,non-medical practitioner,nursing home,hospital,surgery,emergency room(ER) treatment,diagnostic tests, over-night stay,home healthcare services, aids/devices used. Indirect costs associated with functional disability:employment status,willingness to work,work disability due to RA,sick leave,part time work,ability to perform chores,chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale;higher score=higher medical cost.

Outcome measures

SECONDARY outcome

Timeframe: Month 6

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost:visit to doctor,non-medical practitioner,nursing home,hospital,surgery,emergency room(ER) treatment,diagnostic tests, over-night stay,home healthcare services, aids/devices used. Indirect costs associated with functional disability:employment status,willingness to work,work disability due to RA,sick leave,part time work,ability to perform chores,chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale;higher score=higher medical cost.

Outcome measures

SECONDARY outcome

Timeframe: Baseline, Month 3

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=193 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=205 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=102 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:Hospital ER visit(n=14,14,8)	1.21 events Standard Deviation 0.80	1.29 events Standard Deviation 0.47	1.50 events Standard Deviation 0.76	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:RA related ER visit(n=14,13,8)	0.14 events Standard Deviation 0.53	0.15 events Standard Deviation 0.55	0.25 events Standard Deviation 0.46	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:Hospitalization(n=2,6,2)	1.00 events Standard Deviation 0.00	1.17 events Standard Deviation 0.41	1.00 events Standard Deviation 0.00	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:RA related hospitalization(n=2,7,2)	0.50 events Standard Deviation 0.71	0.00 events Standard Deviation 0.00	0.00 events Standard Deviation 0.00	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:Outpatient surgery(n=7,5,2)	1.14 events Standard Deviation 0.38	1.60 events Standard Deviation 0.89	1.00 events Standard Deviation 0.00	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:RA related outpatient surgery(n=7,5,2)	0.29 events Standard Deviation 0.76	0.00 events Standard Deviation 0.00	1.00 events Standard Deviation 1.41	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:Non-study diagnostic test(n=27,25,13)	1.26 events Standard Deviation 0.81	1.60 events Standard Deviation 0.82	1.54 events Standard Deviation 0.78	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:RA related diagnostic test(n=30,26,14)	0.13 events Standard Deviation 0.35	0.15 events Standard Deviation 0.37	0.21 events Standard Deviation 0.43	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:Non-medical practitioner visit(n=4,1,0)	10.75 events Standard Deviation 6.99	7.00 events Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.	NA events Standard Deviation NA Data was not analyzed as no participant was evaluable for this parameter.	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:RA related non-medical visit(n=4,1,0)	0.25 events Standard Deviation 0.50	2.00 events Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.	NA events Standard Deviation NA Data was not analyzed as no participant was evaluable for this parameter.	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:Doctor visit(n=193,204,102)	4.38 events Standard Deviation 4.50	3.85 events Standard Deviation 4.07	3.56 events Standard Deviation 2.73	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:RA related doctor visit (n=192,205,100)	1.26 events Standard Deviation 0.81	1.18 events Standard Deviation 0.85	1.33 events Standard Deviation 0.89	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:Hospital ER visit(n=13,18,10)	1.15 events Standard Deviation 0.38	1.61 events Standard Deviation 1.29	1.40 events Standard Deviation 0.70	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:RA related ER visit(n=12,18,10)	0.75 events Standard Deviation 0.75	0.50 events Standard Deviation 0.62	0.80 events Standard Deviation 0.92	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:Hospitalization(n=14,19,7)	1.07 events Standard Deviation 0.27	1.11 events Standard Deviation 0.32	1.00 events Standard Deviation 0.00	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:RA related hospitalization(n=14,19,8)	1.00 events Standard Deviation 0.55	0.84 events Standard Deviation 0.60	0.88 events Standard Deviation 0.64	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:Outpatient surgery(n=6,11,2)	1.00 events Standard Deviation 0.00	1.00 events Standard Deviation 0.00	1.00 events Standard Deviation 0.00	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:RA related outpatient surgery(n=6,11,3)	0.00 events Standard Deviation 0.00	0.55 events Standard Deviation 0.82	0.00 events Standard Deviation 0.00	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:Non-study diagnostic test(n=39,51,17)	1.69 events Standard Deviation 1.22	1.94 events Standard Deviation 1.22	1.59 events Standard Deviation 1.06	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:RA related diagnostic test(n=41,52,19)	0.61 events Standard Deviation 0.67	0.83 events Standard Deviation 0.94	0.95 events Standard Deviation 0.97	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:Non-medical practitioner visit(n=8,2,2)	12.00 events Standard Deviation 12.99	7.00 events Standard Deviation 7.07	1.00 events Standard Deviation 0.00	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:RA related non-medical visit(n=8,2,2)	1.13 events Standard Deviation 0.64	1.50 events Standard Deviation 0.71	0.50 events Standard Deviation 0.71	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:Doctor visit(n=141,137,66)	3.60 events Standard Deviation 2.40	3.64 events Standard Deviation 3.44	4.00 events Standard Deviation 3.12	—
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:RA related doctor visit(n=142,138,66)	0.83 events Standard Deviation 0.67	0.81 events Standard Deviation 0.81	0.92 events Standard Deviation 0.81	—

SECONDARY outcome

Timeframe: Month 6

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=159 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=152 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=39 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=36 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 6 Non-medical practitioner visit(n=0,2,0,0)	NA events Standard Deviation NA Data was not analyzed as no participant was evaluable for this parameter.	3.00 events Standard Deviation 1.41	NA events Standard Deviation NA Data was not analyzed as no participant was evaluable for this parameter.	NA events Standard Deviation NA Data was not analyzed as no participant was evaluable for this parameter.
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 6 Doctor visit(n=159,152,39,36)	3.22 events Standard Deviation 2.54	3.69 events Standard Deviation 3.18	3.00 events Standard Deviation 2.29	3.69 events Standard Deviation 2.25
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 6 RA related doctor visit(n=159,152,39,36)	0.92 events Standard Deviation 0.70	0.83 events Standard Deviation 0.73	1.05 events Standard Deviation 0.60	0.92 events Standard Deviation 0.69
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 6 Hospital ER visit(n=16,13,3,2)	1.06 events Standard Deviation 0.25	1.25 events Standard Deviation 0.45	3.00 events Standard Deviation 1.73	1.00 events Standard Deviation 0.00
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 6 RA related ER visit(n=16,12,3,2)	0.13 events Standard Deviation 0.34	0.08 events Standard Deviation 0.28	1.67 events Standard Deviation 2.08	0.00 events Standard Deviation 0.00
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 6 Hospitalization(n=5,3,2,2)	1.20 events Standard Deviation 0.45	1.00 events Standard Deviation 0.00	1.50 events Standard Deviation 0.71	1.00 events Standard Deviation 0.00
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 6 RA related hospitalization(n=5,3,2,2)	0.20 events Standard Deviation 0.45	0.33 events Standard Deviation 0.58	0.50 events Standard Deviation 0.71	0.00 events Standard Deviation 0.00
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 6 Outpatient surgery(n=3,10,0,2)	1.00 events Standard Deviation 0.00	1.50 events Standard Deviation 1.58	NA events Standard Deviation NA Data was not analyzed as no participant was evaluable for this parameter.	1.00 events Standard Deviation 0.00
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 6 RA related outpatient surgery(n=3,12,0,2)	0.00 events Standard Deviation 0.00	0.00 events Standard Deviation 0.00	NA events Standard Deviation NA Data was not analyzed as no participant was evaluable for this parameter.	0.00 events Standard Deviation 0.00
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 6 Non-study diagnostic test(n=24,33,7,5)	2.04 events Standard Deviation 1.55	1.39 events Standard Deviation 0.75	2.57 events Standard Deviation 1.62	1.20 events Standard Deviation 0.45
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 6 RA related diagnostic test(n=29,34,6,6)	0.45 events Standard Deviation 0.87	0.29 events Standard Deviation 0.52	0.67 events Standard Deviation 0.82	0.33 events Standard Deviation 0.52
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 6 RA related non-medical visit(n=0,2,0,0)	NA events Standard Deviation NA Data was not analyzed as no participant was evaluable for this parameter.	0.50 events Standard Deviation 0.71	NA events Standard Deviation NA Data was not analyzed as no participant was evaluable for this parameter.	NA events Standard Deviation NA Data was not analyzed as no participant was evaluable for this parameter.

SECONDARY outcome

Timeframe: Baseline, Month 3

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains.Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=139 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=131 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=84 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:Hospital length of stay(n=14,19,7)	15.43 days Standard Deviation 12.33	9.63 days Standard Deviation 7.27	4.29 days Standard Deviation 2.81	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:Hospital length of stay(n=2,6,2)	7.50 days Standard Deviation 6.36	6.33 days Standard Deviation 7.12	12.00 days Standard Deviation 2.83	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:Chores by family(n=81,82,55)	25.72 days Standard Deviation 31.12	27.29 days Standard Deviation 33.02	27.00 days Standard Deviation 30.37	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:Days in nursing home(n=4,2,1)	23.25 days Standard Deviation 2.63	16.50 days Standard Deviation 6.36	10.00 days Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:Days devices/aids used(n=37,31,20)	118.95 days Standard Deviation 134.74	85.52 days Standard Deviation 95.38	55.90 days Standard Deviation 56.66	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:RA related aids used(n=38,31,20)	2.21 days Standard Deviation 1.47	1.90 days Standard Deviation 1.33	1.45 days Standard Deviation 0.69	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:Days of work per week(n=72,84,43)	5.08 days Standard Deviation 1.04	4.92 days Standard Deviation 1.17	5.02 days Standard Deviation 0.96	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:Days on sick leave(n=33,34,25)	25.12 days Standard Deviation 33.23	10.91 days Standard Deviation 18.15	22.40 days Standard Deviation 29.72	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:Days of part time work(n=20,25,12)	15.65 days Standard Deviation 22.74	20.44 days Standard Deviation 26.71	12.42 days Standard Deviation 10.57	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:Paid work, bothered by RA(n=69,68,37)	33.87 days Standard Deviation 31.01	28.15 days Standard Deviation 29.06	38.30 days Standard Deviation 27.52	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:Chores by housekeeper(n=33,43,22)	17.30 days Standard Deviation 24.67	16.63 days Standard Deviation 25.99	14.55 days Standard Deviation 22.32	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Baseline:Chores by family(n=139,131,84)	29.54 days Standard Deviation 31.72	27.85 days Standard Deviation 34.80	22.12 days Standard Deviation 27.36	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:Days in nursing home(n=0,1,1)	NA days Standard Deviation NA Data was not analyzed as no participant was evaluable for this parameter.	2.0 days Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.	10.0 days Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:Days devices/aids used(n=27,20,14)	109.93 days Standard Deviation 107.85	89.50 days Standard Deviation 89.98	94.68 days Standard Deviation 111.05	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:RA related aids used(n=27,20,14)	1.81 days Standard Deviation 1.36	1.50 days Standard Deviation 0.95	1.93 days Standard Deviation 1.21	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:Days of work per week(n=68,79,41)	5.00 days Standard Deviation 0.93	5.05 days Standard Deviation 1.19	4.88 days Standard Deviation 1.17	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:Days on sick leave(n=13,17,10)	15.00 days Standard Deviation 23.59	14.82 days Standard Deviation 23.32	19.60 days Standard Deviation 27.68	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:Days of part time work(n=10,11,9)	12.70 days Standard Deviation 20.97	19.09 days Standard Deviation 25.07	6.22 days Standard Deviation 5.70	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:Paid work, bothered by RA(n=44,44,30)	21.70 days Standard Deviation 26.22	19.39 days Standard Deviation 23.10	26.50 days Standard Deviation 27.03	—
Number of Days as Assessed Using RA-HCRU at Baseline and Month 3 Month 3:Chores by housekeeper(n=26,19,23)	7.73 days Standard Deviation 8.43	6.32 days Standard Deviation 5.73	18.13 days Standard Deviation 25.19	—

SECONDARY outcome

Timeframe: Month 6

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains.Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=74 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=75 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=24 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=21 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Number of Days as Assessed Using RA-HCRU at Month 6 Hospital length of stay(n=5,3,2,2)	13.60 days Standard Deviation 18.28	7.67 days Standard Deviation 5.86	13.50 days Standard Deviation 14.85	1.50 days Standard Deviation 0.71
Number of Days as Assessed Using RA-HCRU at Month 6 Days in nursing home(n=1,1,0,0)	24.00 days Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.	15.00 days Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.	NA days Standard Deviation NA Data was not analyzed as no participant was evaluable for this parameter.	NA days Standard Deviation NA Data was not analyzed as no participant was evaluable for this parameter.
Number of Days as Assessed Using RA-HCRU at Month 6 Days devices/aids used(n=24,13,6,4)	97.17 days Standard Deviation 116.84	53.85 days Standard Deviation 52.29	101.50 days Standard Deviation 106.85	72.25 days Standard Deviation 113.10
Number of Days as Assessed Using RA-HCRU at Month 6 RA related aids used(n=25,12,6,4)	1.48 days Standard Deviation 1.23	1.67 days Standard Deviation 0.98	2.17 days Standard Deviation 1.83	1.75 days Standard Deviation 0.96
Number of Days as Assessed Using RA-HCRU at Month 6 Days of work per week(n=65,75,22,21)	4.95 days Standard Deviation 0.84	5.16 days Standard Deviation 0.99	5.09 days Standard Deviation 1.15	4.71 days Standard Deviation 1.19
Number of Days as Assessed Using RA-HCRU at Month 6 Days on sick leave(n=10,10,3,2)	21.10 days Standard Deviation 27.23	15.50 days Standard Deviation 27.71	9.00 days Standard Deviation 5.20	47.50 days Standard Deviation 60.10
Number of Days as Assessed Using RA-HCRU at Month 6 Days of part time work(n=11,6,3,2)	15.00 days Standard Deviation 25.46	8.50 days Standard Deviation 5.68	5.00 days Standard Deviation 3.00	4.00 days Standard Deviation 4.24
Number of Days as Assessed Using RA-HCRU at Month 6 Paid work, bothered by RA(n=34,32,14,12)	21.09 days Standard Deviation 25.89	12.72 days Standard Deviation 17.50	26.14 days Standard Deviation 29.98	15.92 days Standard Deviation 18.80
Number of Days as Assessed Using RA-HCRU at Month 6 Chores by housekeeper(n=25,13,8,1)	16.32 days Standard Deviation 24.40	20.23 days Standard Deviation 31.76	8.50 days Standard Deviation 11.78	90.00 days Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.
Number of Days as Assessed Using RA-HCRU at Month 6 Chores by family(n=74,64,24,13)	20.38 days Standard Deviation 27.42	28.09 days Standard Deviation 32.55	11.58 days Standard Deviation 18.35	27.38 days Standard Deviation 30.61

SECONDARY outcome

Timeframe: Baseline, Month 3

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=139 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=131 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=82 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Number of Hours Per Day as Assessed RA-HCRU at Baseline and Month 3 Baseline:Home healthcare services(n=1,4,1)	2.00 hours per day Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.	3.75 hours per day Standard Deviation 5.50	1.00 hours per day Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.	—
Number of Hours Per Day as Assessed RA-HCRU at Baseline and Month 3 Baseline:RA related home HC services(n=2,4,1)	1.50 hours per day Standard Deviation 0.71	2.25 hours per day Standard Deviation 2.50	1.00 hours per day Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.	—
Number of Hours Per Day as Assessed RA-HCRU at Baseline and Month 3 Baseline:Work done(n=71,85,43)	7.66 hours per day Standard Deviation 1.87	8.60 hours per day Standard Deviation 6.12	8.95 hours per day Standard Deviation 5.20	—
Number of Hours Per Day as Assessed RA-HCRU at Baseline and Month 3 Baseline:Missed work due to RA(n=19,25,12)	3.47 hours per day Standard Deviation 2.67	10.84 hours per day Standard Deviation 24.54	6.17 hours per day Standard Deviation 12.29	—
Number of Hours Per Day as Assessed RA-HCRU at Baseline and Month 3 Baseline:Chores by housekeeper(n=33,43,22)	5.64 hours per day Standard Deviation 4.06	4.67 hours per day Standard Deviation 2.07	5.86 hours per day Standard Deviation 3.06	—
Number of Hours Per Day as Assessed RA-HCRU at Baseline and Month 3 Baseline:Chores by family(n=139,131,82)	3.99 hours per day Standard Deviation 4.02	3.32 hours per day Standard Deviation 2.89	4.85 hours per day Standard Deviation 6.88	—
Number of Hours Per Day as Assessed RA-HCRU at Baseline and Month 3 Month 3:Home healthcare services(n=2,0,1)	2.50 hours per day Standard Deviation 2.12	NA hours per day Standard Deviation NA Data was not analyzed as no participant was evaluable for this parameter.	1.00 hours per day Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.	—
Number of Hours Per Day as Assessed RA-HCRU at Baseline and Month 3 Month 3:RA related home HC services(n=2,0,1)	0.50 hours per day Standard Deviation 0.71	NA hours per day Standard Deviation NA Data was not analyzed as no participant was evaluable for this parameter.	0.00 hours per day Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.	—
Number of Hours Per Day as Assessed RA-HCRU at Baseline and Month 3 Month 3:Work done(n=66,79,41)	8.20 hours per day Standard Deviation 7.28	7.68 hours per day Standard Deviation 2.37	8.85 hours per day Standard Deviation 5.34	—
Number of Hours Per Day as Assessed RA-HCRU at Baseline and Month 3 Month 3:Missed work due to RA(n=10,9,9)	2.20 hours per day Standard Deviation 1.55	3.67 hours per day Standard Deviation 1.41	9.56 hours per day Standard Deviation 19.04	—
Number of Hours Per Day as Assessed RA-HCRU at Baseline and Month 3 Month 3:Chores by housekeeper(n=27,19,23)	5.74 hours per day Standard Deviation 4.70	5.21 hours per day Standard Deviation 4.89	5.91 hours per day Standard Deviation 4.75	—
Number of Hours Per Day as Assessed RA-HCRU at Baseline and Month 3 Month 3:Chores by family(n=79,82,54)	3.09 hours per day Standard Deviation 1.96	3.82 hours per day Standard Deviation 6.91	3.69 hours per day Standard Deviation 3.82	—

SECONDARY outcome

Timeframe: Month 6

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=74 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=75 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=24 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=21 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Number of Hours Per Days as Assessed Using RA-HCRU at Month 6 Home healthcare services(n=3,1,1,1)	4.00 hours per day Standard Deviation 1.00	1.00 hours per day Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.	0.00 hours per day Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.	1.00 hours per day Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.
Number of Hours Per Days as Assessed Using RA-HCRU at Month 6 RA related home healthcare services(3,1,2,1)	1.00 hours per day Standard Deviation 1.00	1.00 hours per day Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.	0.00 hours per day Standard Deviation 0.00	0.00 hours per day Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.
Number of Hours Per Days as Assessed Using RA-HCRU at Month 6 Work done(n=65,75,22,21)	8.38 hours per day Standard Deviation 5.53	8.43 hours per day Standard Deviation 4.16	7.23 hours per day Standard Deviation 2.11	8.29 hours per day Standard Deviation 1.79
Number of Hours Per Days as Assessed Using RA-HCRU at Month 6 Missed work due to RA(n=11,7,3,2)	2.73 hours per day Standard Deviation 2.53	2.57 hours per day Standard Deviation 1.72	2.67 hours per day Standard Deviation 2.31	1.50 hours per day Standard Deviation 2.12
Number of Hours Per Days as Assessed Using RA-HCRU at Month 6 Chores by housekeeper(n=24,14,8,1)	5.13 hours per day Standard Deviation 2.49	10.57 hours per day Standard Deviation 22.97	5.00 hours per day Standard Deviation 2.45	8.00 hours per day Standard Deviation NA Standard deviation was not estimable as only 1 participant was evaluable.
Number of Hours Per Days as Assessed Using RA-HCRU at Month 6 Chores by family(n=74,64,24,13)	3.11 hours per day Standard Deviation 2.18	2.86 hours per day Standard Deviation 1.80	3.29 hours per day Standard Deviation 2.84	4.69 hours per day Standard Deviation 6.46

SECONDARY outcome

Timeframe: Baseline, Month 3

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=148 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=174 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=79 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Baseline and Month 3 Baseline (n=146, 174, 79)	5.59 units on a scale Standard Deviation 3.17	5.61 units on a scale Standard Deviation 6.42	5.41 units on a scale Standard Deviation 2.94	—
Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Baseline and Month 3 Month 3 (n=138, 148, 75)	3.39 units on a scale Standard Deviation 2.85	3.43 units on a scale Standard Deviation 2.88	4.57 units on a scale Standard Deviation 2.94	—

SECONDARY outcome

Timeframe: Month 6

Population: FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=130 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=138 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=34 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=34 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Month 6	3.22 units on a scale Standard Deviation 2.85	3.18 units on a scale Standard Deviation 3.00	3.21 units on a scale Standard Deviation 2.80	3.94 units on a scale Standard Deviation 3.22

SECONDARY outcome

Timeframe: Baseline, Month 3

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given time point for each group respectively.

WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0\[no loss\] to 100\[complete loss of work\]).

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=124 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=122 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=67 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Work Limitations Questionnaire (WLQ) Score at Baseline and Month 3 Baseline:Time management(n=118, 119, 62)	50.84 units on a scale Standard Deviation 26.52	48.98 units on a scale Standard Deviation 27.17	48.74 units on a scale Standard Deviation 26.44	—
Work Limitations Questionnaire (WLQ) Score at Baseline and Month 3 Baseline:Physical demands(n=117, 119, 66)	51.84 units on a scale Standard Deviation 22.44	49.24 units on a scale Standard Deviation 27.51	51.21 units on a scale Standard Deviation 25.33	—
Work Limitations Questionnaire (WLQ) Score at Baseline and Month 3 Baseline:Mental demands(n=119,120,66)	31.04 units on a scale Standard Deviation 24.05	36.14 units on a scale Standard Deviation 28.41	38.69 units on a scale Standard Deviation 27.76	—
Work Limitations Questionnaire (WLQ) Score at Baseline and Month 3 Baseline:Output demands(n=114, 116, 63)	39.70 units on a scale Standard Deviation 24.76	44.85 units on a scale Standard Deviation 30.23	45.30 units on a scale Standard Deviation 28.11	—
Work Limitations Questionnaire (WLQ) Score at Baseline and Month 3 Baseline:Work loss index(n=124, 122, 67)	10.82 units on a scale Standard Deviation 5.21	11.95 units on a scale Standard Deviation 6.20	12.16 units on a scale Standard Deviation 5.92	—
Work Limitations Questionnaire (WLQ) Score at Baseline and Month 3 Month 3:Time management(n=94, 89, 45)	37.65 units on a scale Standard Deviation 29.03	34.63 units on a scale Standard Deviation 29.91	41.32 units on a scale Standard Deviation 23.28	—
Work Limitations Questionnaire (WLQ) Score at Baseline and Month 3 Month 3:Physical demands(n=98, 90, 46)	51.89 units on a scale Standard Deviation 29.32	46.48 units on a scale Standard Deviation 30.17	46.71 units on a scale Standard Deviation 24.78	—
Work Limitations Questionnaire (WLQ) Score at Baseline and Month 3 Month 3:Mental demands(n=100, 93, 47)	24.64 units on a scale Standard Deviation 27.02	24.62 units on a scale Standard Deviation 29.12	28.54 units on a scale Standard Deviation 26.40	—
Work Limitations Questionnaire (WLQ) Score at Baseline and Month 3 Month 3:Output demands(n=96, 90, 45)	27.03 units on a scale Standard Deviation 24.44	28.31 units on a scale Standard Deviation 29.37	33.41 units on a scale Standard Deviation 23.28	—
Work Limitations Questionnaire (WLQ) Score at Baseline and Month 3 Month 3:Work loss index(n=102, 98, 49)	8.48 units on a scale Standard Deviation 5.60	8.05 units on a scale Standard Deviation 6.63	9.29 units on a scale Standard Deviation 5.66	—

SECONDARY outcome

Timeframe: Month 6

Population: FAS population. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. 'n'=participants evaluable at given parameter for each group respectively.

WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0\[no loss\] to 100\[complete loss of work\]).

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=85 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=85 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=26 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=27 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Work Limitations Questionnaire (WLQ) Score at Month 6 Time management (n=80, 81, 25, 23)	36.27 units on a scale Standard Deviation 29.22	30.42 units on a scale Standard Deviation 28.39	34.40 units on a scale Standard Deviation 25.59	39.86 units on a scale Standard Deviation 30.64
Work Limitations Questionnaire (WLQ) Score at Month 6 Physical demands (n=85, 81, 26, 25)	45.37 units on a scale Standard Deviation 29.86	45.17 units on a scale Standard Deviation 34.14	57.16 units on a scale Standard Deviation 27.63	50.33 units on a scale Standard Deviation 31.74
Work Limitations Questionnaire (WLQ) Score at Month 6 Mental demands (n= 81, 82, 25, 26)	22.66 units on a scale Standard Deviation 25.71	21.61 units on a scale Standard Deviation 29.09	25.84 units on a scale Standard Deviation 24.54	29.77 units on a scale Standard Deviation 29.64
Work Limitations Questionnaire (WLQ) Score at Month 6 Output demands (n= 80, 81, 26, 23)	25.04 units on a scale Standard Deviation 24.29	26.30 units on a scale Standard Deviation 29.40	28.65 units on a scale Standard Deviation 23.90	35.05 units on a scale Standard Deviation 29.32
Work Limitations Questionnaire (WLQ) Score at Month 6 Work loss index (n= 85, 85, 26, 27)	7.85 units on a scale Standard Deviation 5.64	7.60 units on a scale Standard Deviation 6.49	9.07 units on a scale Standard Deviation 5.22	9.23 units on a scale Standard Deviation 6.26

OTHER_PRE_SPECIFIED outcome

Timeframe: 2 weeks

Population: FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Participants assessed the severity of their arthritis pain using a 100 millimeter (mm) visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (most severe pain), measurement on a scale corresponds to the magnitude of their pain.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=59 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=61 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=31 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Time to First Greater Than 1 Day Sequential Decrease in Pain From Baseline for Patient Assessment of Arthritis Pain	3 days	3 days	3 days	—

OTHER_PRE_SPECIFIED outcome

Timeframe: 2 weeks

Population: FAS: all participants who were randomized to study, received at least 1 dose of study drug (CP-690550/placebo), had at least 1 post-baseline measurement, and baseline measurement for change from baseline endpoint. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm Visual Analog Scale where 0 = very well and 100 = very poorly.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg n=59 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=61 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=31 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Time to First Greater Than 1 Day Sequential Decrease in Pain From Baseline for Patient Global Assessment of Arthritis	3 days	3 days	3 days	—

Adverse Events

CP-690550 5 mg (Up To Month 3)

Serious events: 1 serious events

Other events: 80 other events

Deaths: 0 deaths

CP-690550 10 mg (Up To Month 3)

Serious events: 5 serious events

Other events: 84 other events

Deaths: 0 deaths

Placebo (Up To Month 3)

Serious events: 6 serious events

Other events: 40 other events

Deaths: 0 deaths

CP-690550 5 mg (Post Month 3)

Serious events: 6 serious events

Other events: 37 other events

Deaths: 0 deaths

CP-690550 10 mg (Post Month 3)

Serious events: 6 serious events

Other events: 48 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	CP-690550 5 mg (Up To Month 3) n=243 participants at risk CP-690550 5 mg tablet orally twice daily up to Month 3.	CP-690550 10 mg (Up To Month 3) n=245 participants at risk CP-690550 10 mg tablet orally twice daily up to Month 3.	Placebo (Up To Month 3) n=122 participants at risk Matching placebo tablet orally twice daily up to Month 3.	CP-690550 5 mg (Post Month 3) n=304 participants at risk CP-690550 5 mg tablet orally twice daily from Month 3 to Month 6.	CP-690550 10 mg (Post Month 3) n=306 participants at risk CP-690550 10 mg tablet orally twice daily from Month 3 to Month 6.
Ear and labyrinth disorders Vertigo	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.41% 1/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders Vomiting	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.41% 1/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Hepatobiliary disorders Cholecystitis acute	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.41% 1/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Infections and infestations Liver abscess	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.41% 1/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Metabolism and nutrition disorders Hypoglycaemia	0.41% 1/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Musculoskeletal and connective tissue disorders Rheumatoid arthritis	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.82% 1/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine leiomyoma	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.82% 1/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Nervous system disorders Grand mal convulsion	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.82% 1/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Nervous system disorders Transient ischaemic attack	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.82% 1/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Reproductive system and breast disorders Uterine polyp	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.82% 1/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.82% 1/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Surgical and medical procedures Abdominoplasty	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.41% 1/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Surgical and medical procedures Breast prosthesis implantation	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.41% 1/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Vascular disorders Deep vein thrombosis	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.82% 1/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Cardiac disorders Atrial fibrillation	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Cardiac disorders Cardiac arrest	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Cardiac disorders Cardiac failure congestive	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.65% 2/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Cardiac disorders Myocardial infarction	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
General disorders Asthenia	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
General disorders Multi-organ failure	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Infections and infestations Bronchitis	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Infections and infestations Cellulitis	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.66% 2/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Infections and infestations Pyelonephritis	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Infections and infestations Tuberculous pleurisy	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Injury, poisoning and procedural complications Humerus fracture	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Injury, poisoning and procedural complications Lower limb fracture	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Injury, poisoning and procedural complications Patella fracture	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Metabolism and nutrition disorders Diabetes mellitus	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Non-small cell lung cancer	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Respiratory, thoracic and mediastinal disorders Pulmonary fibrosis	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Respiratory, thoracic and mediastinal disorders Sleep apnoea syndrome	0.00% 0/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.82% 1/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.

Other adverse events

Other adverse events
Measure	CP-690550 5 mg (Up To Month 3) n=243 participants at risk CP-690550 5 mg tablet orally twice daily up to Month 3.	CP-690550 10 mg (Up To Month 3) n=245 participants at risk CP-690550 10 mg tablet orally twice daily up to Month 3.	Placebo (Up To Month 3) n=122 participants at risk Matching placebo tablet orally twice daily up to Month 3.	CP-690550 5 mg (Post Month 3) n=304 participants at risk CP-690550 5 mg tablet orally twice daily from Month 3 to Month 6.	CP-690550 10 mg (Post Month 3) n=306 participants at risk CP-690550 10 mg tablet orally twice daily from Month 3 to Month 6.
Gastrointestinal disorders Gastritis	1.2% 3/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.4% 6/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.5% 3/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders Nausea	2.9% 7/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	3.7% 9/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.5% 3/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Blood and lymphatic system disorders Anaemia	1.6% 4/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.4% 6/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	1.6% 2/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.99% 3/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.3% 7/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders Abdominal pain upper	2.5% 6/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	1.6% 4/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders Constipation	2.1% 5/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.0% 5/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.5% 3/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders Diarrhoea	4.5% 11/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	3.7% 9/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.5% 3/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders Dyspepsia	2.1% 5/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.4% 6/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	3.3% 4/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
General disorders Oedema peripheral	2.9% 7/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.0% 5/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.5% 3/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.3% 7/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
General disorders Pyrexia	0.82% 2/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.41% 1/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.5% 3/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Infections and infestations Influenza	0.82% 2/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	1.6% 4/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	3.3% 4/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	1.6% 5/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.0% 6/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Infections and infestations Nasopharyngitis	1.6% 4/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.0% 5/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	1.6% 2/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Infections and infestations Upper respiratory tract infection	4.5% 11/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	3.3% 8/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	4.9% 6/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	4.6% 14/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.6% 8/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Infections and infestations Urinary tract infection	1.6% 4/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	4.1% 10/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.5% 3/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.99% 3/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	3.6% 11/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Investigations Blood creatine phosphokinase increased	1.2% 3/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	4.1% 10/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.82% 1/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Musculoskeletal and connective tissue disorders Arthralgia	0.82% 2/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.82% 2/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.5% 3/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Musculoskeletal and connective tissue disorders Back pain	2.1% 5/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.0% 5/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	1.6% 2/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.33% 1/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.6% 8/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Musculoskeletal and connective tissue disorders Rheumatoid arthritis	2.5% 6/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.82% 2/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Nervous system disorders Dizziness	1.2% 3/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.0% 5/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	3.3% 4/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Nervous system disorders Headache	5.3% 13/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	4.5% 11/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.5% 3/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	3.0% 9/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.3% 7/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Nervous system disorders Paraesthesia	2.5% 6/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.41% 1/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Vascular disorders Hypertension	0.82% 2/243 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.9% 7/245 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	1.6% 2/122 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	1.6% 5/304 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.0% 6/306 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer, Inc.

Phone: 1-800-718-1021

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Publication restrictions are in place

Restriction type: OTHER

Measure	CP-690,550 5 mg n=236 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=239 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=120 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Outpatient surgery(n=236,239,120	1.97 units on a scale Standard Deviation 0.16	1.95 units on a scale Standard Deviation 0.21	1.98 units on a scale Standard Deviation 0.16	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Non-study diagnostic test(n=235,239,120)	1.83 units on a scale Standard Deviation 0.38	1.78 units on a scale Standard Deviation 0.41	1.83 units on a scale Standard Deviation 0.37	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:In nursing home(n=236,239,120)	1.98 units on a scale Standard Deviation 0.13	1.99 units on a scale Standard Deviation 0.09	1.99 units on a scale Standard Deviation 0.09	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Home healthcare services(n=235,239,119)	1.99 units on a scale Standard Deviation 0.09	1.98 units on a scale Standard Deviation 0.13	1.99 units on a scale Standard Deviation 0.09	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Required aids/devices(n=236,239,119)	1.84 units on a scale Standard Deviation 0.37	1.87 units on a scale Standard Deviation 0.34	1.83 units on a scale Standard Deviation 0.38	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Non-medical practitioner(n=236,239,120)	1.97 units on a scale Standard Deviation 0.18	1.99 units on a scale Standard Deviation 0.09	1.98 units on a scale Standard Deviation 0.13	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Currently employed(n=236,239,120)	1.69 units on a scale Standard Deviation 0.46	1.64 units on a scale Standard Deviation 0.48	1.64 units on a scale Standard Deviation 0.48	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Feel well enough to work(n=111,90,57)	1.86 units on a scale Standard Deviation 0.35	1.83 units on a scale Standard Deviation 0.37	1.86 units on a scale Standard Deviation 0.35	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Unable to work due to RA(n=111,93,59)	1.37 units on a scale Standard Deviation 0.48	1.29 units on a scale Standard Deviation 0.46	1.41 units on a scale Standard Deviation 0.50	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Lost job/retired early(n=110,92,58)	1.61 units on a scale Standard Deviation 0.49	1.55 units on a scale Standard Deviation 0.50	1.55 units on a scale Standard Deviation 0.50	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Work disabled due to RA(n=111,91,58)	1.54 units on a scale Standard Deviation 0.50	1.48 units on a scale Standard Deviation 0.50	1.52 units on a scale Standard Deviation 0.50	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Retired(n=116,99,59)	1.57 units on a scale Standard Deviation 0.50	1.57 units on a scale Standard Deviation 0.50	1.49 units on a scale Standard Deviation 0.50	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Sick leave due to RA(n=191,202,99)	1.82 units on a scale Standard Deviation 0.38	1.83 units on a scale Standard Deviation 0.38	1.74 units on a scale Standard Deviation 0.44	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Performed part time work(n=192,202,98)	1.89 units on a scale Standard Deviation 0.31	1.87 units on a scale Standard Deviation 0.34	1.88 units on a scale Standard Deviation 0.33	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Performed paid work(n=191,204,99)	1.64 units on a scale Standard Deviation 0.48	1.66 units on a scale Standard Deviation 0.48	1.62 units on a scale Standard Deviation 0.49	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Unable to do chores(n=235,238,118)	1.36 units on a scale Standard Deviation 0.48	1.32 units on a scale Standard Deviation 0.47	1.30 units on a scale Standard Deviation 0.46	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Seen any doctor(n=236,239,119)	1.19 units on a scale Standard Deviation 0.39	1.15 units on a scale Standard Deviation 0.36	1.17 units on a scale Standard Deviation 0.38	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Treated in emergency room(n=236,239,120)	1.94 units on a scale Standard Deviation 0.23	1.92 units on a scale Standard Deviation 0.26	1.92 units on a scale Standard Deviation 0.28	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Admitted for overnight stay (n=13,18,10)	0.15 units on a scale Standard Deviation 0.55	0.17 units on a scale Standard Deviation 0.51	0.20 units on a scale Standard Deviation 0.63	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Hospitalization(n=236,239,120)	1.94 units on a scale Standard Deviation 0.24	1.92 units on a scale Standard Deviation 0.27	1.94 units on a scale Standard Deviation 0.24	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Chores by housekeeper(n=235,239,119)	1.86 units on a scale Standard Deviation 0.35	1.82 units on a scale Standard Deviation 0.39	1.81 units on a scale Standard Deviation 0.40	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Baseline:Chores by family/friends(n=235,239,118)	1.40 units on a scale Standard Deviation 0.49	1.44 units on a scale Standard Deviation 0.50	1.29 units on a scale Standard Deviation 0.45	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3:Seen any doctor(n=235,228,109)	1.42 units on a scale Standard Deviation 0.49	1.41 units on a scale Standard Deviation 0.49	1.39 units on a scale Standard Deviation 0.49	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3:Treated in emergency room(n=236,229,109)	1.94 units on a scale Standard Deviation 0.24	1.94 units on a scale Standard Deviation 0.24	1.93 units on a scale Standard Deviation 0.26	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3:Admitted for overnight stay (n=14,14,8)	0.29 units on a scale Standard Deviation 0.61	0.43 units on a scale Standard Deviation 0.65	0.50 units on a scale Standard Deviation 0.93	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3:Hospitalization(n=236,228,109)	1.99 units on a scale Standard Deviation 0.09	1.97 units on a scale Standard Deviation 0.16	1.98 units on a scale Standard Deviation 0.13	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3:Outpatient surgery(n=236,229,109)	1.97 units on a scale Standard Deviation 0.17	1.98 units on a scale Standard Deviation 0.15	1.98 units on a scale Standard Deviation 0.13	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3: Non-study diagnostic test(n=236,228,109)	1.87 units on a scale Standard Deviation 0.33	1.88 units on a scale Standard Deviation 0.32	1.87 units on a scale Standard Deviation 0.34	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3: In nursing home(n=236,229,109)	2.00 units on a scale Standard Deviation 0.00	2.00 units on a scale Standard Deviation 0.07	1.99 units on a scale Standard Deviation 0.10	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3: Home healthcare services(n=236,228,108)	1.99 units on a scale Standard Deviation 0.09	2.00 units on a scale Standard Deviation 0.00	1.99 units on a scale Standard Deviation 0.10	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3: Required aids/devices(n=235,228,109)	1.89 units on a scale Standard Deviation 0.32	1.91 units on a scale Standard Deviation 0.28	1.87 units on a scale Standard Deviation 0.34	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3: Non-medical practitioner(n=236,229,109)	1.98 units on a scale Standard Deviation 0.13	2.00 units on a scale Standard Deviation 0.07	2.00 units on a scale Standard Deviation 0.00	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3: Currently employed(n=236,228,109)	1.71 units on a scale Standard Deviation 0.45	1.65 units on a scale Standard Deviation 0.48	1.62 units on a scale Standard Deviation 0.49	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3: Feel well enough to work(n=108,93,50)	1.72 units on a scale Standard Deviation 0.45	1.69 units on a scale Standard Deviation 0.47	1.86 units on a scale Standard Deviation 0.35	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3: Unable to work due to RA(n=107,98,52)	1.51 units on a scale Standard Deviation 0.50	1.48 units on a scale Standard Deviation 0.50	1.35 units on a scale Standard Deviation 0.48	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3: Lost job/retired early(n=107,92,49)	1.68 units on a scale Standard Deviation 0.47	1.70 units on a scale Standard Deviation 0.46	1.59 units on a scale Standard Deviation 0.50	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3: Work disabled due to RA(n=109,92,49)	1.57 units on a scale Standard Deviation 0.50	1.62 units on a scale Standard Deviation 0.49	1.47 units on a scale Standard Deviation 0.50	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3: Retired(n=115,107,51)	1.52 units on a scale Standard Deviation 0.50	1.51 units on a scale Standard Deviation 0.50	1.53 units on a scale Standard Deviation 0.50	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3: Sick leave due to RA(n=180,183,88)	1.93 units on a scale Standard Deviation 0.26	1.91 units on a scale Standard Deviation 0.29	1.89 units on a scale Standard Deviation 0.32	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3: Performed part time work(n=181,180,88)	1.94 units on a scale Standard Deviation 0.23	1.94 units on a scale Standard Deviation 0.24	1.90 units on a scale Standard Deviation 0.30	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3: Performed paid work(n=179,184,88)	1.75 units on a scale Standard Deviation 0.44	1.76 units on a scale Standard Deviation 0.43	1.65 units on a scale Standard Deviation 0.48	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3: Unable to do chores(n=231,227,107)	1.60 units on a scale Standard Deviation 0.49	1.63 units on a scale Standard Deviation 0.49	1.39 units on a scale Standard Deviation 0.49	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3: Chores by housekeeper(n=235,229,108)	1.88 units on a scale Standard Deviation 0.32	1.92 units on a scale Standard Deviation 0.28	1.79 units on a scale Standard Deviation 0.41	—
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Month 3 Month 3: Chores by family/friends(n=234,229,108)	1.65 units on a scale Standard Deviation 0.48	1.64 units on a scale Standard Deviation 0.48	1.49 units on a scale Standard Deviation 0.50	—

Measure	CP-690,550 5 mg n=229 Participants CP-690,550 5 milligram (mg) tablet orally twice daily up to Month 6.	CP-690,550 10 mg n=216 Participants CP-690,550 10 mg tablet orally twice daily up to Month 6.	Placebo n=54 Participants Matching placebo tablet orally twice daily up to Month 3.	Placebo, Then CP-690,550 10 mg n=50 Participants Matching placebo tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily from Month 3 up to Month 6 or early termination.
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Lost job/retired early(n=126,102,24,23)	1.73 units on a scale Standard Deviation 0.45	1.63 units on a scale Standard Deviation 0.49	1.54 units on a scale Standard Deviation 0.51	1.57 units on a scale Standard Deviation 0.51
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Work disabled due to RA(n=125,103,24,23)	1.62 units on a scale Standard Deviation 0.49	1.54 units on a scale Standard Deviation 0.50	1.54 units on a scale Standard Deviation 0.51	1.43 units on a scale Standard Deviation 0.51
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Retired(n=126,110,25,23)	1.51 units on a scale Standard Deviation 0.50	1.45 units on a scale Standard Deviation 0.50	1.56 units on a scale Standard Deviation 0.51	1.48 units on a scale Standard Deviation 0.51
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Seen any doctor(n=227,216,54,50)	1.30 units on a scale Standard Deviation 0.46	1.30 units on a scale Standard Deviation 0.46	1.28 units on a scale Standard Deviation 0.45	1.28 units on a scale Standard Deviation 0.45
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Treated in emergency room(n=229,216,54,50)	1.93 units on a scale Standard Deviation 0.26	1.94 units on a scale Standard Deviation 0.24	1.94 units on a scale Standard Deviation 0.23	1.96 units on a scale Standard Deviation 0.20
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Admitted for overnight stay (n=16,13,3,2)	0.25 units on a scale Standard Deviation 0.58	0.23 units on a scale Standard Deviation 0.44	1.33 units on a scale Standard Deviation 2.31	1.00 units on a scale Standard Deviation 1.41
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Hospitalization(n=229,216,54,50)	1.98 units on a scale Standard Deviation 1.15	1.99 units on a scale Standard Deviation 1.12	1.96 units on a scale Standard Deviation 1.19	1.96 units on a scale Standard Deviation 0.20
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Outpatient surgery(n=229,216,54,50)	1.99 units on a scale Standard Deviation 0.11	1.94 units on a scale Standard Deviation 0.23	2.00 units on a scale Standard Deviation 0.00	1.96 units on a scale Standard Deviation 0.20
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Diagnostic test(n=229,216,54,50)	1.87 units on a scale Standard Deviation 0.34	1.84 units on a scale Standard Deviation 0.37	1.87 units on a scale Standard Deviation 0.34	1.88 units on a scale Standard Deviation 0.33
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:In nursing home(n=229,216,54,50)	2.00 units on a scale Standard Deviation 0.07	2.00 units on a scale Standard Deviation 0.07	2.00 units on a scale Standard Deviation 0.00	2.00 units on a scale Standard Deviation 0.00
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Home healthcare services(n=229,216,54,49)	1.99 units on a scale Standard Deviation 0.11	2.00 units on a scale Standard Deviation 0.07	1.96 units on a scale Standard Deviation 0.19	1.98 units on a scale Standard Deviation 0.14
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Required aids/devices(n=229,216,54,50)	1.89 units on a scale Standard Deviation 0.31	1.94 units on a scale Standard Deviation 0.24	1.89 units on a scale Standard Deviation 0.32	1.92 units on a scale Standard Deviation 0.27
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Non-medical practitioner(n=229,216,54,50)	2.00 units on a scale Standard Deviation 0.00	1.99 units on a scale Standard Deviation 0.10	1.98 units on a scale Standard Deviation 0.14	2.00 units on a scale Standard Deviation 0.00
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Currently employed(n=229,216,54,50)	1.71 units on a scale Standard Deviation 0.46	1.65 units on a scale Standard Deviation 0.48	1.59 units on a scale Standard Deviation 0.50	1.58 units on a scale Standard Deviation 0.50
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Feel well enough to work(n=124,101,24,22)	1.73 units on a scale Standard Deviation 0.45	1.66 units on a scale Standard Deviation 0.47	1.71 units on a scale Standard Deviation 0.46	1.73 units on a scale Standard Deviation 0.46
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Unable to work due to RA(n=123,105,24,24)	1.50 units on a scale Standard Deviation 0.50	1.46 units on a scale Standard Deviation 0.50	1.54 units on a scale Standard Deviation 0.51	1.42 units on a scale Standard Deviation 0.50
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Sick leave due to RA(n=175,169,41,41)	1.94 units on a scale Standard Deviation 0.23	1.94 units on a scale Standard Deviation 0.24	1.93 units on a scale Standard Deviation 0.26	1.95 units on a scale Standard Deviation 0.22
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Performed part time work(n=173,170,40,41)	1.93 units on a scale Standard Deviation 0.25	1.96 units on a scale Standard Deviation 0.19	1.93 units on a scale Standard Deviation 0.27	1.95 units on a scale Standard Deviation 0.22
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Performed paid work(n=172,169,39,41)	1.80 units on a scale Standard Deviation 0.40	1.80 units on a scale Standard Deviation 0.40	1.64 units on a scale Standard Deviation 0.49	1.73 units on a scale Standard Deviation 0.45
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Unable to do chores(n=229,214,52,50)	1.62 units on a scale Standard Deviation 0.49	1.69 units on a scale Standard Deviation 0.46	1.54 units on a scale Standard Deviation 0.50	1.70 units on a scale Standard Deviation 0.46
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Chores by housekeeper(n=229,216,54,50)	1.89 units on a scale Standard Deviation 0.31	1.94 units on a scale Standard Deviation 0.25	1.85 units on a scale Standard Deviation 0.36	1.98 units on a scale Standard Deviation 0.14
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 6 Month 6:Chores by family/friends(n=229,216,54,50)	1.67 units on a scale Standard Deviation 0.47	1.70 units on a scale Standard Deviation 0.46	1.54 units on a scale Standard Deviation 0.50	1.74 units on a scale Standard Deviation 0.44